Johnson & Johnson is facing a critical test over its $10B proposal to end litigation alleging that its baby powder caused ovarian cancer, as it tries to convince a judge to sign off on its third attempt to resolve thousands of lawsuits through a subsidiary’s bankruptcy, Reuters’ Dietrich Knauth reports. J&J believes the proposed deal has enough support to succeed after two previous failures.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson (NYSE:JNJ) Goes to Court for Third Time over $10B Talc Bankruptcy Plan
- Senate votes to confirm Robert Kennedy as head of HHS
- Genmab upgraded to Outperform from Market Perform at Leerink
- CVS Health, Lyft report Q4 results: Morning Buzz
- Johnson & Johnson (JNJ) Plans $1 Billion Sale of ‘Cerenovus’ Stroke Unit